PSMA PET/CT-guided biopsy finds hidden prostate cancers that MRI misses

For men whose multiparametric MRI scans come back negative or inconclusive despite persistently elevated PSA levels or other warning signs, the diagnostic road ahead has long been frustrating and uncertain. A new prospective study published in the September issue of The Journal of Nuclear Medicine suggests that a molecular imaging technique already widely used to stage advanced prostate cancer may also solve one of its most stubborn early-detection problems. Researchers at IRCCS Azienda Ospedaliero-Universitaria di Bologna in Italy found that targeted prostate biopsy guided by PSMA PET/CT detected clinically significant prostate cancer in 37 percent of men with negative or equivocal MRI findings, compared with just 21 percent using conventional systematic biopsy alone. When the two approaches were combined, the detection rate climbed to 41 percent, a figure that nearly doubles the yield of the standard pathway and points to a meaningful shift in how diagnostically challenging patients could be managed.

The clinical dilemma the study addresses is well known to urologists and nuclear medicine physicians alike. Multiparametric MRI has become the cornerstone of modern prostate cancer detection, allowing clinicians to localize suspicious lesions, direct biopsy needles toward the most concerning regions, and spare many men unnecessary sampling of slow-growing tumors that may never require treatment. Yet the technology is not infallible. According to the researchers, up to 20 to 30 percent of clinically significant prostate cancers may be missed in patients whose MRI scans are negative or equivocal. For these men, a reassuring scan does not actually rule out dangerous disease, and the standard response—repeated or extended systematic biopsies—carries its own burden of bleeding, infection, anxiety, and cost, all while aggressive tumors can still slip through the sampling grid.

“A negative or unclear MRI does not completely rule out clinically significant prostate cancer. As a result, some men may undergo repeated or extensive biopsies, while relevant tumors may still be missed,” said Andrea Farolfi, MD, a nuclear medicine physician at the Nuclear Medicine Unit of IRCCS Azienda Ospedaliero-Universitaria di Bologna and the study’s lead author. “Determining whether PSMA PET can refine risk stratification and guide targeted sampling for these men could have a direct impact on clinical decision-making.” The rationale behind the approach rests on the biology of the prostate-specific membrane antigen, or PSMA, a protein that is overexpressed on the surface of prostate cancer cells, and often to a far greater degree in aggressive, high-grade disease than in indolent tissue.

PSMA PET/CT exploits this molecular signature by pairing a radiolabeled ligand that binds to PSMA with the anatomic precision of computed tomography. When the radiotracer accumulates intensely within a prostatic region, it signals not merely anatomic distortion, as MRI might show, but active metabolic expression of a marker tightly linked to tumor aggressiveness. In the FUPERMAN study, the researchers enrolled 63 men with negative or inconclusive multiparametric MRI scans who nonetheless carried persistent clinical suspicion of prostate cancer. Each participant underwent gallium-68 PSMA-11 PET/CT followed by prostate biopsy performed with PET fusion guidance, meaning the targeting information from the molecular image was directly co-registered with the biopsy system in real time. A subset of 11 patients additionally underwent dynamic total-body PET, an emerging technique that captures the kinetic behavior of the tracer as it flows into and binds within tissue.

The results were striking in their consistency. PSMA PET/CT was positive in 25 of the 26 men who were ultimately diagnosed with clinically significant prostate cancer, indicating that the molecular image rarely overlooked disease that biopsy later confirmed. PSMA PET/CT-targeted biopsy alone detected clinically significant cancer in 37 percent of the entire study population, while systematic biopsy alone managed only 21 percent. Combining the two strategies raised the detection rate to 41 percent, demonstrating that the molecularly guided approach does not simply duplicate what systematic sampling finds—it uncovers cancers that the conventional grid-based method misses, particularly in prostatic zones where MRI provided no suspicious target to aim at.

Beyond simple detection, the study explored whether quantitative information from the PET scan itself could predict which patients harbored aggressive disease. The researchers found that SUVmax, the maximum standardized uptake value reflecting the peak concentration of radiotracer in a lesion, was independently associated with clinically significant prostate cancer. In other words, the intensity of the molecular signal carried prognostic weight, offering a semiquantitative bridge between imaging and pathology that could help clinicians decide which men truly need biopsy and which might be safely monitored. This kind of risk stratification is precisely what the field has been seeking for the MRI-negative population, where current guidelines offer limited guidance and clinical judgment often defaults to repeat invasive procedures.

The exploratory dynamic total-body PET component added a further layer of technical sophistication. By acquiring continuous imaging data immediately after tracer injection, dynamic total-body PET allows researchers to characterize the kinetics of radiotracer uptake and washout within prostatic lesions. In the 11 patients studied with this protocol, the investigators observed distinct kinetic patterns in aggressive lesions, particularly in cases where MRI findings were unclear. While the subset was small and the analysis explicitly exploratory, the finding hints at a future in which the temporal behavior of PSMA binding—how quickly tracer accumulates and how persistently it is retained—could complement static uptake measurements and further sharpen the distinction between indolent and clinically threatening disease.

“Our findings suggest that PSMA PET/CT could provide an additional tool for identifying men who remain at risk despite non-diagnostic MRI findings and for directing the biopsy toward the most suspicious area,” Farolfi said. “If confirmed in larger studies, this approach could make the diagnostic pathway more accurate and personalized.” The implications for patient care extend beyond the immediate detection statistics. For men caught in the diagnostic gray zone—elevated PSA, negative or equivocal MRI, and mounting pressure for repeat biopsy—a positive PSMA PET/CT could concentrate sampling where it matters most, potentially reducing the number of biopsy cores required, lowering complication rates, and sparing men with truly negative molecular imaging from yet another round of invasive sampling.

The study, titled “PSMA PET/CT–Targeted Biopsy in Men with Negative or Equivocal Multiparametric MRI and Exploratory Dynamic Total-Body PET: The FUPERMAN Study,” was conducted by a multidisciplinary team spanning nuclear medicine, urology, radiology, and internal medicine at the University of Bologna and its teaching hospital. The collaboration reflects the practical demands of the technique itself, which requires nuclear medicine physicians to interpret molecular images, radiologists to reconcile them with prior MRI data, and urologists to execute fusion-guided biopsies with millimeter-level precision. The research was published in The Journal of Nuclear Medicine, the flagship journal of the Society of Nuclear Medicine and Molecular Imaging, and carries the DOI 10.2967/jnumed.126.272108.

As with any single-center study of modest size, the findings will need validation in larger, multi-institutional cohorts before PSMA PET/CT-guided biopsy becomes a standard recommendation for the MRI-negative population. Questions remain about cost-effectiveness, radiation exposure, access to PSMA radiotracers, and whether the impressive detection rates hold across more diverse patient populations. Nevertheless, the FUPERMAN results mark an important proof of concept: a molecular imaging modality originally developed for staging advanced disease can, when fused with biopsy guidance, illuminate cancers that the anatomical gold standard cannot see. For the substantial minority of men whose MRI scans fail them, that could mean the difference between an aggressive tumor caught early and one discovered only after it has progressed beyond the gland.

Subject of Research: PSMA PET/CT-guided targeted biopsy for detecting clinically significant prostate cancer in men with negative or equivocal MRI

Article Title: PSMA PET/CT-targeted biopsy improves detection of clinically significant prostate cancer

Article References: PSMA PET/CT-targeted biopsy improves detection of clinically significant prostate cancer. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: PSMA PET/CT, prostate cancer, targeted biopsy, multiparametric MRI, clinically significant cancer, total-body PET, SUVmax, risk stratification, nuclear medicine, FUPERMAN study, fusion-guided biopsy, diagnostic imaging